Peritoneal (Abdominal Mesothelioma)
New Imidazo[2,1- b][1,3,4]Thiadiazole Derivatives Inhibit FAK Phosphorylation and Potentiate the Antiproliferative Effects of Gemcitabine Through Modulation of the Human Equilibrative Nucleoside Transporter-1 in Peritoneal Mesothelioma
Anticancer Research 2020 September [Link] Giovanna Li Petri, Camilla Pecoraro, Ornella Randazzo, Silvia Zoppi, Stella Maria Cascioferro, Barbara Parrino, Daniela Carbone, Btissame El Hassouni, Andrea Cavazzoni, Nadia Zaffaroni, Girolamo Cirrincione, Patrizia Diana, Godefridus J Peters, Elisa Giovannetti Abstract Background/aim: A new class of imidazo[2,1-b][1,3,4]thiadiazole compounds have recently been evaluated as inhibitors of phosphorylation of focal…
Read MoreAsbestos conceives Fe(II)-dependent mutagenic stromal milieu through ceaseless macrophage ferroptosis and β-catenin induction in mesothelium
Redox Biology 2020 September [Link] Fumiya Ito, Izumi Yanatori, Yuki Maeda, Kenta Nimura, Satoki Ito, Tasuku Hirayama, Hideko Nagasawa, Norihiko Kohyama, Yasumasa Okazaki, Shinya Akatsuka, Shinya Toyokuni Abstract Asbestos is still a social burden worldwide as a carcinogen causing malignant mesothelioma. Whereas recent studies suggest that local iron reduction is a preventive strategy against carcinogenesis,…
Read MoreMulticystic peritoneal mesothelioma treated with complete cytoreductive surgery, peritonectomy and hyperthermic intra-peritoneal chemotherapy-A case report
International Journal of Surgery Case Reports 2020 [Link] Naveen Padmanabhan, Haruaki Ishibashi, Kazurou Nishihara, Shouzou Sako, Kanji Katayama, Satoshi Wakama, Yasuyuki Kamada, Yutaka Yonemura Abstract Background: Multicystic Peritoneal mesothelioma is a rare and distinct variety of peritoneal mesothelioma with borderline malignant potential. Conventional Tumor bulking has been associated with recurrence of 45-50 %. Hence a…
Read MoreAdvances with pharmacotherapy for peritoneal metastasis
Expert Opinion on Pharmacotherapy 2020 August 12 [Link] Yutaka Yonemura, Haruaki Iahibashi, Shouzou Sako, Akiyoshi Mizumoto, Nobuyuki Takao, Masumi Ichinose, Shunsuke Motoi, Yang Liu, Satoshi Wakama, Yasuyuki Kamada, Kazurou Nishihara Abstract Introduction: A new treatment strategy involving cytoreductive surgery (CRS) combined with perioperative intraperitoneal (IP) chemotherapy was proposed in 1999 by the Peritoneal Surface Oncology…
Read MoreNew vistas in malignant mesothelioma: MicroRNA architecture and NRF2/MAPK signal transduction
Life Sciences 2020 July 22 [Link] Manav Gandhi, Sujit Nair Abstract Malignant mesothelioma (MM) is a cancer of the mesothelial lining of the pleura, peritoneum, pericardium and testes. The most common form is asbestos-linked MM that is etiologically linked to repeated asbestos exposure with a long latency period, although non-asbestos MM has also been reported.…
Read MoreTesting for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology
Cancer Cytopathology 2020 July 17 [Link] Martin Chevrier, Sara E Monaco, Jacob A Jerome, Francoise Galateau-Salle, Andrew Churg, Sanja Dacic Abstract Background: A number of ancillary tests have been developed that aid in the diagnosis of mesothelioma in cytology specimens. The aim of this retrospective study was to determine whether testing for BAP1 and CDKN2A/p16…
Read MoreGenomic Profiling of Multiple Primary Cancers Including Synchronous Lung Adenocarcinoma and Bilateral Malignant Mesotheliomas: Identification of a Novel BAP1 Germline Variant
Pathology International 2020 June 24 [Link] Aya Shinozaki-Ushiku, Shinji Kohsaka, Hidenori Kage, Katsutoshi Oda, Kiyoshi Miyagawa, Jun Nakajima, Hiroyuki Aburatani, Hiroyuki Mano, Tetsuo Ushiku Abstract We report a case with a rare combination of synchronous lung adenocarcinoma and bilateral malignant pleural mesotheliomas in a 70-year-old male without asbestos exposure. He metachronously developed peritoneal malignant mesothelioma,…
Read MoreCisplatin Plus Pemetrexed Therapy and Subsequent Immune Checkpoint Inhibitor Administration for Malignant Peritoneal Mesothelioma Without Pleural Lesions: Case Report
Medicine 2020 May 29 [Link] Hiroaki Ikushima, Toshio Sakatani, Sayaka Ohara, Hideyuki Takeshima, Hajime Horiuchi, Teppei Morikawa, Kazuhiro Usui Abstract Rationale: Malignant peritoneal mesothelioma is a rare tumor with a poor prognosis and has no recommended therapy after first-line pemetrexed and platinum-based chemotherapy. Moreover, effects of immune checkpoint inhibitors on peritoneal mesothelioma remains to be…
Read MoreMalignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge
Cancers 2020 May 7 [Link] David Michael Abbott, Chandra Bortolotto, Silvia Benvenuti, Andrea Lancia, Andrea Riccardo Filippi, Giulia Maria Stella Abstract Mesothelioma is a malignancy of serosal membranes including the peritoneum, pleura, pericardium and the tunica vaginalis of the testes. Malignant mesothelioma (MM) is a rare disease with a global incidence in countries like Italy…
Read MoreSurvivin Expression as an Independent Predictor of Overall Survival in Malignant Peritoneal Mesothelioma
Oncology Letters 2020 June [Link] Guozun Zhang, Dong-Liang Yang, Guoqi Zheng, Yufei Liang Abstract Malignant peritoneal mesothelioma (MPeM) is an incurable cancer strongly associated with asbestos exposure and characterised by poor prognosis. The aim of the present study was to elucidate the prognostic and predictive value of CD146 and survivin expression in MPeM. Diagnostic biopsies…
Read More